Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma

Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rei Hashimoto, Etsuko Tanabe, Yoshihisa Otsuka, Yukihiro Yoneda, Yasufumi Kageyama
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	anti-ma2 antibody encephalitis immune checkpoint inhibitor paraneoplastic neurological syndrome mesothelioma Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c3369f45964146f897fd6cf07623e336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3369f45964146f897fd6cf07623e336
record_format	dspace
spelling	oai:doaj.org-article:c3369f45964146f897fd6cf07623e3362021-12-02T12:40:22ZAnti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma1662-680X10.1159/000519763https://doaj.org/article/c3369f45964146f897fd6cf07623e3362021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519763https://doaj.org/toc/1662-680XNeurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy.Rei HashimotoEtsuko TanabeYoshihisa OtsukaYukihiro YonedaYasufumi KageyamaKarger Publishersarticleanti-ma2 antibodyencephalitisimmune checkpoint inhibitorparaneoplastic neurological syndromemesotheliomaNeurology. Diseases of the nervous systemRC346-429ENCase Reports in Neurology, Vol 13, Iss 3, Pp 724-728 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-ma2 antibody encephalitis immune checkpoint inhibitor paraneoplastic neurological syndrome mesothelioma Neurology. Diseases of the nervous system RC346-429
spellingShingle	anti-ma2 antibody encephalitis immune checkpoint inhibitor paraneoplastic neurological syndrome mesothelioma Neurology. Diseases of the nervous system RC346-429 Rei Hashimoto Etsuko Tanabe Yoshihisa Otsuka Yukihiro Yoneda Yasufumi Kageyama Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
description	Neurological adverse events of immune checkpoint inhibitor (ICI) therapy mostly develop within 3 months after initiation of ICI treatment. An 82-year-old male with malignant pleural mesothelioma developed anti-Ma2-associated limbic encephalitis at a delay of 18 months after the start of nivolumab therapy (3 months after termination of a 15-month course of ICI treatment). Immunotherapy with steroids and immunoglobulins resulted in moderate neurological improvement. Over the next year, malignant pleural mesothelioma gradually worsened, while the anti-Ma2 antibody test remained positive. Anti-Ma2 paraneoplastic encephalitis may occur after a delay following the discontinuation of ICI therapy.
format	article
author	Rei Hashimoto Etsuko Tanabe Yoshihisa Otsuka Yukihiro Yoneda Yasufumi Kageyama
author_facet	Rei Hashimoto Etsuko Tanabe Yoshihisa Otsuka Yukihiro Yoneda Yasufumi Kageyama
author_sort	Rei Hashimoto
title	Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_short	Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_full	Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_fullStr	Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_full_unstemmed	Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma
title_sort	anti-ma2-associated limbic encephalitis after termination of immune checkpoint inhibitor therapy for malignant pleural mesothelioma
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/c3369f45964146f897fd6cf07623e336
work_keys_str_mv	AT reihashimoto antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma AT etsukotanabe antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma AT yoshihisaotsuka antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma AT yukihiroyoneda antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma AT yasufumikageyama antima2associatedlimbicencephalitisafterterminationofimmunecheckpointinhibitortherapyformalignantpleuralmesothelioma
_version_	1718393765706596352

Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma

Ejemplares similares